ECSP088171A - Metodo para la prediccion de la respuesta a un tratamiento - Google Patents

Metodo para la prediccion de la respuesta a un tratamiento

Info

Publication number
ECSP088171A
ECSP088171A EC2008008171A ECSP088171A ECSP088171A EC SP088171 A ECSP088171 A EC SP088171A EC 2008008171 A EC2008008171 A EC 2008008171A EC SP088171 A ECSP088171 A EC SP088171A EC SP088171 A ECSP088171 A EC SP088171A
Authority
EC
Ecuador
Prior art keywords
marker gene
growth factor
response
treatment
patient
Prior art date
Application number
EC2008008171A
Other languages
English (en)
Inventor
Joachim Moecks
Andreas Strauss
Gerhard Zugmaier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088171(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088171A publication Critical patent/ECSP088171A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)

Abstract

La invención está relacionada con un método para la predicción de la respuesta a un tratamiento con un inhibidor de la dimerización de HER en un paciente, lo que comprende los pasos de valorar un gen marcador o una combinación de genes marcadores seleccionados de entre el grupo que consiste en el gen marcador del factor de crecimiento epidérmico, del factor de crecimiento transformante alfa y de HER2 o una combinación de genes marcadores que consiste en el gen marcador de la anfiregulina y un gen marcador seleccionado del gen marcador del factor de crecimiento epidérmico, del factor de crecimiento transformante alfa y de HER2, en una muestra biológica del paciente y la predicción de la respuesta al tratamiento con el inhibidor de la dimerización de HER en el paciente mediante la evaluación de los resultados del primer paso. Se describen usos adicionales y métodos en los que estos marcadores se utilizan.
EC2008008171A 2005-08-12 2008-02-11 Metodo para la prediccion de la respuesta a un tratamiento ECSP088171A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12

Publications (1)

Publication Number Publication Date
ECSP088171A true ECSP088171A (es) 2008-03-26

Family

ID=35511140

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008171A ECSP088171A (es) 2005-08-12 2008-02-11 Metodo para la prediccion de la respuesta a un tratamiento

Country Status (32)

Country Link
US (2) US7700299B2 (es)
EP (2) EP2196547B1 (es)
JP (1) JP2009504142A (es)
KR (2) KR20080034922A (es)
CN (2) CN101705287A (es)
AR (1) AR057323A1 (es)
AT (2) ATE539171T1 (es)
AU (2) AU2006281746B2 (es)
BR (1) BRPI0615001A2 (es)
CA (1) CA2616913A1 (es)
CL (1) CL2010000720A1 (es)
CR (1) CR9686A (es)
CY (1) CY1111612T1 (es)
DE (1) DE602006019265D1 (es)
DK (1) DK1915460T3 (es)
EC (1) ECSP088171A (es)
ES (1) ES2356066T3 (es)
HR (1) HRP20110171T1 (es)
IL (1) IL188923A0 (es)
MA (1) MA31549B1 (es)
MX (1) MX2008001926A (es)
NO (1) NO20080371L (es)
NZ (1) NZ565270A (es)
PL (1) PL1915460T3 (es)
PT (1) PT1915460E (es)
RS (1) RS51859B (es)
RU (2) RU2408735C2 (es)
SI (1) SI1915460T1 (es)
TW (1) TW200741010A (es)
UA (1) UA93989C2 (es)
WO (1) WO2007019899A2 (es)
ZA (1) ZA201102688B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN104383535A (zh) 2000-05-19 2015-03-04 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CA2592177A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
ZA200707078B (en) * 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
ES2370054T3 (es) * 2005-08-24 2011-12-12 Bristol-Myers Squibb Company Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico.
DK2132573T3 (da) * 2007-03-02 2014-07-14 Genentech Inc Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
CA2710680C (en) * 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
KR20160066557A (ko) * 2008-03-14 2016-06-10 제넨테크, 인크. 약물 저항성과 관련된 유전적 변이
AU2009246398A1 (en) 2008-05-14 2009-11-19 Bristol-Myers Squibb Company Predictors of patient response to treatment with EGF receptor inhibitors
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
CA2749817A1 (en) * 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-2 expression
CA2749846C (en) * 2009-01-15 2018-08-07 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-3
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US9518988B2 (en) * 2010-04-18 2016-12-13 Yeda Research And Development Co. Ltd. Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseases
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
EP3763419A1 (en) * 2011-01-07 2021-01-13 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
AU2012318541B2 (en) * 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
BR112014007521A8 (pt) 2011-10-14 2018-04-10 Genentech Inc método para estender a sobrevida livre de progressão em uma população com câncer de mama, artigo de fabricação, método para produção de um artigo de fabricação, para garantir o uso seguro e efetivo de pertuzumabe, de tratar câncer de mama, bolsa intravenosa, método de tratar câncer gástrico, de tratar adenocarcinoma do estômago e de melhora de sobrevida
EA201491335A1 (ru) 2012-01-06 2015-04-30 Элселикс Терапьютикс, Инк. Бигуанидные композиции и способы лечения метаболических расстройств
EA033067B1 (ru) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
WO2015017529A2 (en) * 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
EP3581586A1 (en) 2014-04-25 2019-12-18 F. Hoffmann-La Roche AG Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
EP3791891A1 (en) 2014-07-17 2021-03-17 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
LT3302551T (lt) 2015-05-30 2024-09-10 F. Hoffmann-La Roche Ag Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai
JP2018527286A (ja) * 2015-07-17 2018-09-20 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (zh) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Her-2的荧光免疫层析检测方法及试剂盒
TW201818940A (zh) 2016-11-04 2018-06-01 美商建南德克公司 Her2陽性乳癌之治療
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
KR20210134432A (ko) 2017-01-17 2021-11-09 제넨테크, 인크. 피하 her 2 항체 제형
CN110337450B (zh) 2017-03-02 2023-07-25 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
CN112368382B (zh) * 2018-05-25 2024-11-01 柏业公司 用于预防和治疗纤维化相关疾病和呼吸系统疾病的双调蛋白基因特异性双链寡核苷酸和包含其的组合物
IL299376A (en) 2020-06-29 2023-02-01 Genentech Inc Fixed dose combination of pertuzumab plus transtuzumab
KR20250057808A (ko) * 2022-08-09 2025-04-29 헬리제닉스 아이엔씨. 유전자 변이의 임상적 관련성을 평가하는 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
KR100628846B1 (ko) 1996-10-18 2006-09-29 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
ES2486265T3 (es) 2002-03-13 2014-08-18 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
PT1585966E (pt) * 2002-07-15 2012-02-20 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
JP4609930B2 (ja) * 2002-12-11 2011-01-12 ベンタナ・メディカル・システムズ・インコーポレーテッド Ｈｅｒ−２指向性治療に対する応答を予測する方法
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
AU2004225439A1 (en) 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
WO2005049829A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Process
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
US20080113344A1 (en) 2003-10-28 2008-05-15 Ralph Wirtz Methods and Compositions for the Response Prediction of Malignant Neoplasia to Treatment
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
RU2300111C2 (ru) * 2005-06-15 2007-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ прогнозирования течения заболевания раком молочной железы

Also Published As

Publication number Publication date
KR20080034922A (ko) 2008-04-22
EP1915460A2 (en) 2008-04-30
AR057323A1 (es) 2007-11-28
PT1915460E (pt) 2011-03-17
CA2616913A1 (en) 2007-02-22
US20070037228A1 (en) 2007-02-15
EP2196547A1 (en) 2010-06-16
KR20110074921A (ko) 2011-07-04
MX2008001926A (es) 2008-03-24
TW200741010A (en) 2007-11-01
ZA201102688B (en) 2012-01-25
MA31549B1 (fr) 2010-08-02
US7700299B2 (en) 2010-04-20
CL2010000720A1 (es) 2010-12-03
DE602006019265D1 (de) 2011-02-10
AU2006281746B2 (en) 2011-06-23
RU2408735C2 (ru) 2011-01-10
PL1915460T3 (pl) 2011-05-31
US20100112603A1 (en) 2010-05-06
UA93989C2 (ru) 2011-03-25
EP2196547B1 (en) 2011-12-28
JP2009504142A (ja) 2009-02-05
CN101705287A (zh) 2010-05-12
RU2008108907A (ru) 2009-09-20
AU2011202339A1 (en) 2011-06-09
CY1111612T1 (el) 2015-10-07
WO2007019899A2 (en) 2007-02-22
EP1915460B1 (en) 2010-12-29
WO2007019899A8 (en) 2010-08-05
NO20080371L (no) 2008-05-09
BRPI0615001A2 (pt) 2011-04-26
RU2010115252A (ru) 2011-10-27
WO2007019899A3 (en) 2007-04-05
CR9686A (es) 2008-02-20
NZ565270A (en) 2011-05-27
RS51859B (sr) 2012-02-29
CN101405405A (zh) 2009-04-08
IL188923A0 (en) 2008-08-07
ATE539171T1 (de) 2012-01-15
AU2006281746A1 (en) 2007-02-22
HRP20110171T1 (hr) 2011-04-30
ES2356066T3 (es) 2011-04-04
DK1915460T3 (da) 2011-01-31
SI1915460T1 (sl) 2011-04-29
ATE493514T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
ECSP088171A (es) Metodo para la prediccion de la respuesta a un tratamiento
AR102518A1 (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40
CR9747A (es) Secuencias de nucleotidos que codifican proteinas insecticidas
MX2024004195A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
AR059433A1 (es) Identificacion y uso de genes blanco para el control de nematodos parasitos de plantas
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
MX392170B (es) Método para determinar la secuencia de un acido nucleico usando luminiscencia resuelta por tiempo.
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
ATE483825T1 (de) Zusammensetzungen für die identifizierung von adenoviren
WO2007053245A3 (en) Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes
EP4428528A3 (en) Labeled nucleotide compositions and methods for nucleic acid sequencing
MX2021008867A (es) Composiciones reactantes marcadas de intensidad alta y metodos de secuenciamiento.
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
MX339340B (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
BRPI0816016B8 (pt) kit reagente para analisar uma amostra e método para analisar uma amostra
WO2018096375A3 (en) Determination of the receptive status of the endometrium
EP1987165A4 (en) Gene with influence on the human memory
WO2008060833A3 (en) Composition, method, system, and kit for optical electrophysiology
AR055437A1 (es) Deteccion de metilacion genetica
AR104805A1 (es) Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet
TN2009000348A1 (en) A method of identification of cells that show sensitivity to modulation of signaling mediated by a fibroblast growth factor receptor or a variant thereof
AR077993A1 (es) Combinacion de marcadores de adn para caracterizar y realizar fingerprinting de un aislado de lactobacillus sakei